|
|
Home > Corporate Social Responsibility > Anti
HIV/AIDS
|
|
Anti
HIV/AIDS
Ranbaxy comprehensive anti-HIV portfolio comprises Bio-Equivalent Anti-Retrovirals (ARVs) and Anti-Infectives for Opportunistic infections
Ranbaxy, in its endeavor to make ARVs accessible to patients around the world, is leveraging its global network of offices, affiliates, joint ventures and alliances. With Ranbaxy products being marketed in over 125 countries and ground operations in 46 countries, Ranbaxy provides pre & post sales support to institutions, NGOs, and Ministries of Health, making Ranbaxy ARVs available in their respective treatment programs Several humanitarian and government programmes have sourced ARVs from Ranbaxy. Some of them being MoH-Nigeria, MSF in various countries, MDM-Cambodia, MEDS in Kenya, etc. In Zambia, the Ministry of Health has lauded Ranbaxy's initiative in making available quality ARVs at reasonable prices in that country. In Latin America, Ranbaxy's ARVs have been registered in Brazil, Peru, Venezuela and Guatemala among other countries. In South East Asia, ARVs are being marketed in Vietnam, Cambodia and Myanmar already. Besides, regulatory filings are on in several countries in these regions.
Encouraged by the positive response to its efforts to make quality anti-HIV generics, Ranbaxy is committed to working on all possible fronts and seeking partnerships to improve access to these medicines.
Ranbaxy offers a complete basket of pharmaceuticals for several first line HAART regimens. The current portfolio is the largest range of bio-equivalent generic ARVs available from a single company. These products are manufactured at Ranbaxy's WHO prequalified and USFDA approved facilities.
- Several Ranbaxy ARVs approved by USFDA and WHO
- First Asian pharmaceutical company to get approval for a generic ARV from USFDA
- Over 250 approvals of ARVs across 40 countries, with 130 more in pipeline
- Only company using both WHO & USFDA approved API supplier
- Bioequivalence studies conducted at leading CROs in North America
- All ARVs comply with Zone IV and Zone II stability requirements
- Leading supplier of ARVs to global NGOs, Institutions & Government programs
- Ranbaxy's ARVs have catered to treatment programs in over 50 countries globally
- Ranbaxy's quality FDCs reduce pill burden and improve patient compliance
|
 |
For HIV/ AIDS Product Portfolio, please Click Here |
|
|
